Restless Legs Syndrome (RLS) Background information for medical media outside the US only This selection gives an overview on background material for Restless Legs Syndrome (RLS) available on the Boehringer Ingelheim corporate website.

Press Releases

• 17 April 2008New data confirm pramipexole (Mirapexin®/Sifrol®) can significantly reduce sleep disturbance for people with Restless Legs Syndrome (RLS)
• 08 June 2007Efficacy of Boehringer Ingelheim's pramipexole (Mirapexin®/Sifrol®) also demonstrated in patients with daytime RLS symptoms
• 10 November 2006FDA approves Boehringer Ingelheim's pramipexole for the treatment of moderate-to-severe primary Restless Legs Syndrome (RLS).
• press release archive

Documents

• Restless Legs Syndrome: Results of a Large Polysomnographic Study - PDF (45 KB)
• Backgrounder: Restless Leg Syndrom (RLS) - PDF (68 KB)
• Glossary - PDF (46 KB)
• Annual Report 2007: Page 51 - PDF (4.9 MB)

Related Links

• FENS research award
• Focus on Clincal Research - interactive animation
• Media event: Restless Legs Syndrome, Brussel, Belgium 2007: Dispelling the Mystery Behind Restless Legs Syndrome
• Research & Development

External Links

• Boehringer Ingelheim Global Clinical Trials website